Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LEXX

LEXX - Lexaria Bioscience Corp. Stock Price, Fair Value and News

$1.07+0.01 (+0.94%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

LEXX Price Action

Last 7 days

-4.5%

Last 30 days

2.9%

Last 90 days

11.5%

Trailing 12 Months

-60.4%

LEXX RSI Chart

LEXX Valuation

Market Cap

23.8M

Price/Earnings (Trailing)

-2.5K

Price/Sales (Trailing)

33.69

EV/EBITDA

-9

Price/Free Cashflow

-2.27

LEXX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

705.9K

Rev. Growth (Yr)

107.14%

LEXX Earnings

Earnings (TTM)

-9.6K

Earnings Growth (Yr)

520.93%

Earnings Growth (Qtr)

342.71%

LEXX Profitability

Operating Margin

96.30%

EBT Margin

-321.80%

Return on Equity

-0.37%

Return on Assets

-0.23%

Free Cashflow Yield

-44.05%

LEXX Investor Care

Shares Dilution (1Y)

27.35%

Diluted EPS (TTM)

-0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025525.9K615.9K705.9K0
2024404.7K411.0K464.3K496.9K
2023328.6K306.6K226.2K279.8K
2022489.1K372.2K255.4K339.3K
2021650.3K817.9K722.7K605.9K
2020406.7K250.5K252.6K495.9K
2019501.1K628.6K670.9K626.6K
2018183.5K219.3K289.1K325.8K
201748.5K68.6K64.0K113.9K
201667.7K69.8K86.5K45.8K
201543.7K44.8K45.9K62.6K
2014863.1K394.4K159.1K42.5K
20131.5M1.6M1.3M1.1M
20121.1M978.6K1.1M1.4M
20110001.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Lexaria Bioscience Corp.

LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications, including hypertension, heart disease, dementia, and diabetes. It is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna, Canada.
 CEO
 WEBSITEhttps://lexariabioscience.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Lexaria Bioscience Corp. Frequently Asked Questions

What is the ticker symbol for Lexaria Bioscience Corp.? What does LEXX stand for in stocks?

LEXX is the stock ticker symbol of Lexaria Bioscience Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexaria Bioscience Corp. (LEXX)?

As of Wed Dec 03 2025, market cap of Lexaria Bioscience Corp. is 23.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LEXX stock?

You can check LEXX's fair value in chart for subscribers.

Is Lexaria Bioscience Corp. a good stock to buy?

The fair value guage provides a quick view whether LEXX is over valued or under valued. Whether Lexaria Bioscience Corp. is cheap or expensive depends on the assumptions which impact Lexaria Bioscience Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LEXX.

What is Lexaria Bioscience Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, LEXX's PE ratio (Price to Earnings) is -2479.06 and Price to Sales (PS) ratio is 33.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LEXX PE ratio will change depending on the future growth rate expectations of investors.